AR099630A1 - Preparación de un inhibidor de mek y formulación que lo comprende - Google Patents

Preparación de un inhibidor de mek y formulación que lo comprende

Info

Publication number
AR099630A1
AR099630A1 ARP130103796A ARP130103796A AR099630A1 AR 099630 A1 AR099630 A1 AR 099630A1 AR P130103796 A ARP130103796 A AR P130103796A AR P130103796 A ARP130103796 A AR P130103796A AR 099630 A1 AR099630 A1 AR 099630A1
Authority
AR
Argentina
Prior art keywords
compound
mixture
formula
solution
suspension
Prior art date
Application number
ARP130103796A
Other languages
English (en)
Inventor
Nichols Paul
J Stengel Peter
Liu Weidong
Zimmermann Daniel
Wolf Marie
Heinz Christine - Pachinger Werner
Andreas Niederer Daniel
Misun Marian
Max Krell Christoph
Original Assignee
Novartis Ag
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50488781&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR099630(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Array Biopharma Inc filed Critical Novartis Ag
Publication of AR099630A1 publication Critical patent/AR099630A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un proceso para preparar (2-hidroxietioxi)-amida de ácido 6-(4-bromo-2-fluorofenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-carboxílico Compuesto A, de fórmula (4), el proceso comprende los pasos de: a) hacer reaccionar un compuesto de la fórmula (1) con una base adecuada para formar un intermedio; y b) hacer reaccionar dicho intermedio con un compuesto de la fórmula (2) para proporcionar un compuesto de la fórmula (3) o un hidrato de este, donde P¹ es un grupo protector; c) disolver dicho compuesto de la fórmula (3) o un hidrato de este en un solvente o sistema de solventes adecuado; y d) desproteger dicho compuesto de fórmula (3) o un hidrato de este con un reactivo de desprotección adecuado, donde P¹ en cada aparición puede ser el mismo o diferente, y es un grupo protector adecuado, para proporcionar el Compuesto A. Reivindicación 12: El proceso de la reivindicación 1 que comprende adicionalmente las etapas de: a) disolver el Compuesto A en una solución que comprende (i.) un sistema de solventes que comprende un éter y opcionalmente un alcohol y (ii.) agua para proporcionar una solución; b) agregar una suspensión de gérmenes cristalinos a la solución para proporcionar una mezcla de suspensión; c) enfriar la mezcla de suspensión para proporcionar una mezcla de suspensión enfriada; d) agregar agua a la mezcla de suspensión enfriada para proporcionar una mezcla tratada; y e) enfriar la mezcla tratada para proporcionar el Compuesto A cristalizado. Reivindicación 24: Un proceso para preparar (2-hidroxietioxi)-amida de ácido 6-(4-bromo-2-fluorofenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-carboxílico (Compuesto A), el proceso comprende los pasos de: a) disolver el Compuesto A en una solución que comprende (i.) un sistema de solventes que comprende un éter y opcionalmente un alcohol, y (ii.) agua para proporcionar una solución; b) agregar una suspensión de gérmenes cristalinos a la solución para proporcionar una mezcla de suspensión; c) enfriar la mezcla de suspensión para proporcionar una mezcla de suspensión enfriada; d) agregar agua a la mezcla de suspensión enfriada para proporcionar una mezcla tratada; y e) enfriar la mezcla tratada para proporcionar (2-hidroxietioxi)-amida del ácido 6-(4-bromo-2-fluorofenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-carboxílico cristalizado.
ARP130103796A 2012-10-19 2013-10-18 Preparación de un inhibidor de mek y formulación que lo comprende AR099630A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261716169P 2012-10-19 2012-10-19

Publications (1)

Publication Number Publication Date
AR099630A1 true AR099630A1 (es) 2016-08-10

Family

ID=50488781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103796A AR099630A1 (es) 2012-10-19 2013-10-18 Preparación de un inhibidor de mek y formulación que lo comprende

Country Status (23)

Country Link
US (7) US9238627B2 (es)
EP (3) EP4306171A3 (es)
JP (3) JP6385939B2 (es)
CN (3) CN104870427B (es)
AR (1) AR099630A1 (es)
BR (1) BR112015008623B1 (es)
CA (2) CA3079071C (es)
CY (1) CY1122670T1 (es)
DK (2) DK2909182T3 (es)
ES (2) ES2772498T3 (es)
FI (1) FI3702351T3 (es)
HK (1) HK1214254A1 (es)
HR (1) HRP20240033T1 (es)
HU (2) HUE047708T2 (es)
JO (1) JOP20130304B1 (es)
LT (1) LT3702351T (es)
PL (2) PL2909182T3 (es)
PT (2) PT2909182T (es)
RS (1) RS65117B1 (es)
RU (2) RU2018127873A (es)
SI (2) SI2909182T1 (es)
TW (1) TWI650316B (es)
WO (1) WO2014063024A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079071C (en) 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
SG11201810793XA (en) * 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations
EP3712133A4 (en) * 2017-11-14 2021-05-12 Shenzhen TargetRx, Inc. SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION WITH IT
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11395823B2 (en) * 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
MX2023003867A (es) 2020-10-05 2023-04-18 Pf Medicament Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2024003942A1 (en) * 2022-07-01 2024-01-04 Natco Pharma Limited An improved process for the preparation of selumetinib sulfate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU49401A (sh) * 1999-01-13 2004-07-15 Warner-Lambert Company Benzoheterocikli i njihova upotreba kao inhibitori mek
WO2001005390A2 (en) * 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
NZ535158A (en) * 2002-03-13 2007-06-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
BRPI0412851A (pt) * 2003-07-24 2006-10-03 Warner Lambert Co benzamidazóis de n-metila-substituìdos
BRPI0611993B1 (pt) 2005-06-23 2023-11-28 Array Biopharma, Inc. Compostos de benzimidazol e seu processo de preparação
CA2612296A1 (en) 2005-06-23 2007-01-04 Array Biopharma Inc. Snar process for preparing benzimidazole compounds
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2007071951A1 (en) * 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
EP2227469B9 (en) * 2007-11-12 2014-09-10 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
EA201101533A1 (ru) 2009-04-21 2012-05-30 Новартис Аг Гетероциклические соединения в качестве ингибиторов mek
CA3079071C (en) * 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same

Also Published As

Publication number Publication date
US20200171002A1 (en) 2020-06-04
CA2888474C (en) 2021-03-02
US10398683B2 (en) 2019-09-03
CA3079071C (en) 2022-06-07
US20160168103A1 (en) 2016-06-16
US9238627B2 (en) 2016-01-19
HUE065433T2 (hu) 2024-05-28
PT2909182T (pt) 2020-03-02
CY1122670T1 (el) 2021-03-12
HRP20240033T1 (hr) 2024-03-29
WO2014063024A1 (en) 2014-04-24
EP4306171A3 (en) 2024-04-03
CA2888474A1 (en) 2014-04-24
CN109336824A (zh) 2019-02-15
RU2018127873A (ru) 2019-03-14
JP2019194272A (ja) 2019-11-07
ES2772498T3 (es) 2020-07-07
EP2909182B1 (en) 2019-12-04
SI2909182T1 (sl) 2020-03-31
BR112015008623B1 (pt) 2022-10-25
CA3079071A1 (en) 2014-04-24
US20160168104A1 (en) 2016-06-16
TW201427956A (zh) 2014-07-16
TWI650316B (zh) 2019-02-11
HUE047708T2 (hu) 2020-05-28
EP2909182A4 (en) 2016-07-06
PL2909182T3 (pl) 2020-06-01
EP3702351B1 (en) 2023-11-22
EP2909182A1 (en) 2015-08-26
DK2909182T3 (da) 2020-02-17
ES2971077T3 (es) 2024-06-03
EP3702351A1 (en) 2020-09-02
SI3702351T1 (sl) 2024-03-29
CN109336824B (zh) 2022-11-11
JP2016503391A (ja) 2016-02-04
RS65117B1 (sr) 2024-02-29
PL3702351T3 (pl) 2024-04-02
JP6385939B2 (ja) 2018-09-05
FI3702351T3 (fi) 2024-01-24
US9382212B1 (en) 2016-07-05
US20180296533A1 (en) 2018-10-18
DK3702351T3 (da) 2024-01-29
JP6737838B2 (ja) 2020-08-12
LT3702351T (lt) 2024-01-10
PT3702351T (pt) 2024-01-17
US20160168102A1 (en) 2016-06-16
US20140128442A1 (en) 2014-05-08
US9980944B2 (en) 2018-05-29
CN109456272A (zh) 2019-03-12
HK1214254A1 (zh) 2016-07-22
EP4306171A2 (en) 2024-01-17
US9598376B2 (en) 2017-03-21
RU2669391C2 (ru) 2018-10-11
RU2015118572A (ru) 2016-12-20
CN104870427A (zh) 2015-08-26
US9562016B2 (en) 2017-02-07
CN104870427B (zh) 2018-10-23
US20170231963A1 (en) 2017-08-17
JP2018135399A (ja) 2018-08-30
US10729678B2 (en) 2020-08-04
JOP20130304B1 (ar) 2021-08-17
BR112015008623A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
AR099630A1 (es) Preparación de un inhibidor de mek y formulación que lo comprende
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
HRP20160241T1 (hr) Postupci i intermedijeri za pripravu jak inhibitora
CO7160029A2 (es) Compuestos de heterociclilo como inhibidores de mek
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112014001801A2 (pt) indazóis
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
AR098871A1 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
BR112013016637A2 (pt) processo para a preparação de derivados de 3-alquil-sulfinilbenzoíla
AR087344A1 (es) Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c
PE20142331A1 (es) Metodo para preparar un compuesto mediante la reaccion de adicion de michael novedosa usando agua o varios acidos como aditivo
AR089080A1 (es) Proceso de recuperacion de clorhidrato de nalmefeno
BR112017025135A2 (pt) processos para isolar um composto e para preparar um composto
AR113853A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
BR112018076239A2 (pt) método para produzir cristal de composto de ura-cil
PE20130014A1 (es) Hidrato del hidrobromuro de agomelatina y preparacion de este
AR094240A1 (es) Proceso para producir cristal de compuesto de pirazol
MX366784B (es) Metodo para producir una formulacion liquida emulsionable que comprende un plaguicida de piripiropeno.
AR087993A1 (es) Procesos e intermediarios para la preparacion de un inhibidor macrociclico de la proteasa del hcv

Legal Events

Date Code Title Description
FC Refusal